Michael Barbella, Managing Editor06.25.24
Veristat has named Rachel Page as chief commercial officer (CCO) to succeed Cindy Henderson, who recently assumed the chief strategy officer (CSO) role in order to help develop and execute the company’s customer-driven corporate strategy.
With more than two decades of experience in global health and science commercialization, Page is poised to leverage Veristat's deep industry expertise. Her role will be crucial in assisting companies as they navigate their most complex clinical and regulatory challenges to speed the delivery of innovative therapies.
“Veristat has a 30-year history of driving innovative approaches that help deliver what are often breakthrough therapies to patients in need,” Veristat CEO Patrick Flanagan said. “Rachel’s accomplishments and experience empowering people, building commercial organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan. Rachel has received tremendous recognition for her unwavering commitment to client success. I am confident in her ability to leverage Veristat’s deep industry experience on a global scale.”
Page's extensive global network and her successful history in all phases of the pharmaceutical lifecycle will be instrumental in delivering impactful results for clients.
“I am thrilled to join this dynamic, science-driven team," Page commented. "Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations. I am honored to collaborate with executives, colleagues, and clients who are dedicated to accelerating the availability of groundbreaking treatments for patients with complex conditions. I am eager to lead our talented global commercial team and contribute to achieving our clients’ vital objectives."
In her new role, Page will oversee Veristat’s commercialization strategy and operations, including business development, proposals, contracts, marketing, and fostering robust client relationships. She will also focus on the growth and development of the commercial team, ensuring continued success in meeting our clients’ needs.
Veristat is the Science-First contract research organization and consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.
With more than two decades of experience in global health and science commercialization, Page is poised to leverage Veristat's deep industry expertise. Her role will be crucial in assisting companies as they navigate their most complex clinical and regulatory challenges to speed the delivery of innovative therapies.
“Veristat has a 30-year history of driving innovative approaches that help deliver what are often breakthrough therapies to patients in need,” Veristat CEO Patrick Flanagan said. “Rachel’s accomplishments and experience empowering people, building commercial organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan. Rachel has received tremendous recognition for her unwavering commitment to client success. I am confident in her ability to leverage Veristat’s deep industry experience on a global scale.”
Page's extensive global network and her successful history in all phases of the pharmaceutical lifecycle will be instrumental in delivering impactful results for clients.
“I am thrilled to join this dynamic, science-driven team," Page commented. "Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations. I am honored to collaborate with executives, colleagues, and clients who are dedicated to accelerating the availability of groundbreaking treatments for patients with complex conditions. I am eager to lead our talented global commercial team and contribute to achieving our clients’ vital objectives."
In her new role, Page will oversee Veristat’s commercialization strategy and operations, including business development, proposals, contracts, marketing, and fostering robust client relationships. She will also focus on the growth and development of the commercial team, ensuring continued success in meeting our clients’ needs.
Veristat is the Science-First contract research organization and consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.